Objectives: We sought to evaluate the impact of a strategy of reduced-dose fibrinolytic
acceleration of ST-segment elevation myocardial infarction (STEMI) treatment followed by …

Background Time-to-treatment is important for survival in patients with acute myocardial
infarction (AMI) treated with fibrinolytic therapy, but the importance of time-to-treatment with …

BACKGROUND: Plasminogen activator therapy for acute myocardial infarction is limited by
lack of achievement of early, complete, and sustained reperfusion in a substantial proportion …

BACKGROUND: Although considered the highest level of evidence and critical-to-test novel
therapies, clinical trials are unrepresentative of the “real world” as they lack a true patient …

Dr Eric Topol, Cleveland Clinic, Cleveland, Ohio, presented the third Global Use of
STrategies to Open occluded coronary arteries (GUSTO III) study. This was a randomized …

Objectives: We sought to determine if an underlying mechanism of the association between
prolonged symptom-to-treatment times and adverse outcomes may be an association of …

Background In an in vitro model, recombinant tissue-type plasminogen activator was
significantly more effective than streptokinase in dissolving 24-hour-old human blood clots …

Background Revascularization rates vary substantially between countries in patients with
acute ST-elevation myocardial infarction (STEMI). The impact of early revascularization on …

Background Fibrinolytic therapy offers an alternative to mechanical reperfusion for ST-
segment elevation myocardial infarction (STEMI) in settings where health-care resources …

goal. 10, 11 These are summarized in Table 1. Together, these factors likely account for the
inability to achieve TIMI grade 3 perfusion in at least 40% of instances. Moreover, even …